En Carta Diagnostics
Develops at-home molecular diagnostic tests intended to detect Lyme disease and sexually transmitted infections.
Overview
En Carta Diagnostics is developing at-home molecular tests for infectious diseases, with initial focus areas including Lyme disease and sexually transmitted infections. Its products target decentralized diagnostics for patients and care pathways that may benefit from home-based sample collection or testing. The company’s stated differentiator is bringing molecular testing into an at-home format for conditions that often require timely detection. En Carta Diagnostics raised a reported $5 million undisclosed round to bring its Lyme disease and STI tests to market.
Funding History
En Carta Diagnostics raises €5 million to bring at-home molecular tests for Lyme disease and STIs to market
Frequently Asked Questions
- How much has En Carta Diagnostics raised in total?
- En Carta Diagnostics has raised a total of $5M across 1 funding round.
- Who are En Carta Diagnostics's investors?
- En Carta Diagnostics's investors include Blue Forest Ventures.
- What does En Carta Diagnostics do?
- En Carta Diagnostics is developing at-home molecular tests for infectious diseases, with initial focus areas including Lyme disease and sexually transmitted infections. Its products target decentralized diagnostics for patients and care pathways that may benefit from home-based sample collection or testing. The company’s stated differentiator is bringing molecular testing into an at-home format for conditions that often require timely detection. En Carta Diagnostics raised a reported $5 million undisclosed round to bring its Lyme disease and STI tests to market.
- Where is En Carta Diagnostics headquartered?
- En Carta Diagnostics is headquartered in San Francisco, CA.
Investors
Related Insights
A comprehensive analysis of Isembard's funding history, investors, competitive position, and growth trajectory in the Deep Tech space.
Compare the leading AI-focused VC firms: Andreessen Horowitz, Sequoia Capital, Thrive Capital, and 7 more. Analysis of 150+ AI deals, investment strategies, sector focus, and portfolio performance.
395 AI funding deals worth $337B tracked in 2026. Complete guide to raising pre-seed, seed, Series A/B/C+ for AI startups. Valuations, metrics VCs demand, top investors (Sequoia, a16z, Lightspeed), and how AI funding differs from traditional tech. Includes real deal sizes, timelines, and founder strategies.